Protara Therapeutics (TARA) Research & Development (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Research & Development of $13.6 million for Q1 2026, up 48.25% year-over-year from $9.1 million in Q1 2025, and up 3.34% quarter-over-quarter from $13.1 million in Q4 2025.
Protara Therapeutics (TARA) Research & Development (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Research & Development for 14 consecutive years, with $13.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 48.25% year-over-year to $13.6 million; the TTM figure through Mar 2026 stood at $47.0 million (up 42.12% YoY), while the FY2025 annual figure was $42.6 million, up 34.47% from the prior year.
- Research & Development climbed to $13.6 million in Q1 2026 per TARA's latest filing, from $13.1 million in the prior quarter.
- Across five years, Research & Development topped out at $13.6 million in Q1 2026 and bottomed at $3.1 million in Q2 2022.
- Historically, Research & Development has averaged $7.6 million across 5 years, with a median of $7.2 million in 2023.
- Annual changes were most pronounced in 2022 — Research & Development tumbled 47.61% — and 2023, when it jumped 134.99%.
- Protara Therapeutics' Research & Development stood at $5.0 million in 2022, then rose by 27.9% to $6.4 million in 2023, then jumped by 48.86% to $9.5 million in 2024, then soared by 38.16% to $13.1 million in 2025, then advanced by 3.34% to $13.6 million in 2026.
- Business Quant data shows TARA's Research & Development at $13.6 million in Q1 2026, $13.1 million in Q4 2025, and $9.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | 16.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.96 Mn |
| Mar 31, 2026 | 13.56 Mn |
| Dec 31, 2025 | 13.12 Mn |
| Sep 30, 2025 | 9.59 Mn |
| Jun 30, 2025 | 10.77 Mn |
| Mar 31, 2025 | 9.15 Mn |
| Dec 31, 2024 | 9.50 Mn |
| Sep 30, 2024 | 8.07 Mn |
| Jun 30, 2024 | 6.39 Mn |
| Mar 31, 2024 | 7.75 Mn |
| Dec 31, 2023 | 6.38 Mn |
| Sep 30, 2023 | 6.22 Mn |
| Jun 30, 2023 | 7.25 Mn |
| Mar 31, 2023 | 5.14 Mn |
| Dec 31, 2022 | 4.99 Mn |
| Sep 30, 2022 | 3.47 Mn |
| Jun 30, 2022 | 3.08 Mn |
| Mar 31, 2022 | 5.27 Mn |
| Dec 31, 2021 | -16.34 Mn |
| Sep 30, 2021 | 4.09 Mn |